FDA Approval Marks Breakthrough in AI-Driven Liver Disease Research
The US Food and Drug Administration has approved AIM-NASH, the world’s first artificial intelligence–powered tool designed specifically to support drug development for metabolic dysfunction-associated steatohepatitis (MASH). The approval marks a pivotal advance in clinical research, offering a pathway toward faster and more consistent biopsy evaluations—one of the most time-intensive steps in liver disease trials.
Month: Current Affairs - December 10, 2025
Category: FDA regulatory approvals